18:13 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

Redx to test antifibrotic in clinic for NASH in 2020

Redx Pharma plc (LSE:REDX) said its lead Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor reduced collagen deposition in animal models of lung, kidney and liver fibrosis. The company also said the compound has a...
04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
19:58 , Jun 15, 2018 |  BC Week In Review  |  Financial News

Ahead of new trials, Kadmon raises $100M

Kadmon Holdings Inc. (NYSE:KDMN) added $0.35 (10%) to $3.68 on June 12 after it raised $100 million in two offerings through the sale of 30.3 million shares at $3.30. The company sold the shares in...
20:20 , Jun 12, 2018 |  BC Extra  |  Financial News

Kadmon raises $100M ahead of new trials

Kadmon Holdings Inc. (NYSE:KDMN) added $0.35 (10%) to $3.68 on Tuesday after it raised $100 million in two offerings through the sale of 30.3 million shares at $3.30. The company sold the shares in a...
13:07 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Kadmon reports Phase II data for IPF candidate

Kadmon Holdings Inc. (NYSE:KDMN) reported top-line data from the U.S. Phase II KD025-207 trial of KD025 to treat idiopathic pulmonary fibrosis (IPF) in patients previously treated with or offered Esbriet pirfenidone or Ofev nintedanib. The...
00:23 , Feb 14, 2018 |  BC Extra  |  Clinical News

Kadmon falls after Phase II IPF data

Kadmon Holdings Inc. (NYSE:KDMN) fell $1.03 (21%) to $3.81 on Tuesday after reporting top-line data from the Phase II KD025-207 trial of KD025 to treat idiopathic pulmonary fibrosis in patients previously treated with or offered...
04:55 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Kadmon reports Phase IIa data for chronic GvDH candidate

Kadmon Holdings Inc. (NYSE:KDMN) reported data from the Phase IIa KD025-208 trial evaluating KD025 to treat steroid-dependent or steroid-refractory chronic graft-versus-host disease (GvHD) in patients who have received an allogeneic bone marrow transplant (BMT) or...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
21:36 , Sep 29, 2017 |  BC Week In Review  |  Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

On Sept. 26, several biotechs announced public financing, including follow-ons from Kadmon Holdings Inc. (NYSE:KDMN) and TherapeuticsMD Inc. (NYSE-M:TXMD). Kadmon raised $80 million through the sale of 26.8 million shares at $3 in a bumped-up...
00:00 , Sep 27, 2017 |  BC Extra  |  Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

On Tuesday, several biotechs announced public financing, including follow-ons from Kadmon Holdings Inc. (NYSE:KDMN) and TherapeuticsMD Inc. (NYSE-M:TXMD). Kadmon raised $72 million through the sale of 24 million shares at $3 in a follow-on and...